Daxor Corporation

08/13/2025

Your goal isn't to win big - just tilt the table slightly in your patient's favor. ⚖️

📖Read full story here: https://www.linkedin.com/pulse/how-precision-data-tilts-table-patient-care-daxorcorporation-v06ye/?trackingId=ohgFt4NFQ4yp0%2BEPuKHNnA%3D%3D

08/12/2025

We were honored to ring the Nasdaq Closing Bell commemorating the FDA 510(k) clearance for our new, hand-held Daxor BVA™! 🔔

The replay link and full details are in our latest press release. Read more here: https://daxor.com/daxor-corporation-announces-replay-of-nasdaq-closing-bell-ceremony-now-available/

08/11/2025

We're celebrating! 🎉 The new Daxor BVA™ system just received FDA 510(k) clearance! Our CEO Michael Feldschuh marked the milestone by leading the Nasdaq Closing Bell.🔗to learn more: https://daxor.com/new-daxor-bva/
U.S. Food and Drug Administration




2025 Nasdaq, Inc.

08/08/2025

https://www.facebook.com/share/v/1FpX5ieYqy/?mibextid=wwXIfr

08/07/2025

! Daxor’s next generation blood volume analysis device changes the game by delivering even faster, precise blood volume data —from the hospital to the outpatient clinic. Read more: https://daxor.com/daxor-corporation-receives-fda-clearance-for-new-rapid-lightweight-blood-volume-analysis-system/
Nasdaq

07/23/2025

stakes are high. What if we could prevent it? offers vital fluid data that informs treatment decisions, helping to prevent complications before they happen. Read more: https://linkedin.com/pulse/shifting-aki-from-reaction-prevention-daxorcorporation-cjpwe

The local groups we're working with are seeing something remarkable - AKI incidents have been significantly reduced during diuresis. They're using BVA's normalized hematocrit as their guide.

07/22/2025

📢 ! Proud to announce is expanding! We're now in three new leading facilities, showing the increasing recognition of BVA's impact on patient outcomes and savings. Read full story: https://daxor.com/daxors-blood-volume-analysis-technology-accelerates-market-penetration-with-three-new-facility-adoptions/
Nasdaq

07/21/2025

SGLT-2 inhibitors work in through multiple mechanisms—volume optimization being one key pathway. proves this mechanism with objective data. Read more in this month’s BVA Brief. https://www.linkedin.com/pulse/bva-technology-proves-sglt-2s-volume-advantage-daxorcorporation-lojcc

Objective Data on Volume Optimization Where Traditional Methods Fall Short SGLT-2 inhibitors exert their beneficial effects in heart failure through several pathways, but blood volume analysis (BVA) offers a unique advantage by objectively quantifying their volume optimization effects—providing cl...

07/03/2025

We celebrate the freedom to innovate and heal. At Daxor, we're proud to advance healthcare with precision blood volume measurement technology. Here's to the spirit of independence that drives medical breakthroughs!

06/23/2025

👋 We are thrilled to welcome Mary Beth, our newest team member! Let's make great things happen together! 🥳

06/16/2025

🔍 When this 68-year-old's didn't respond to diuretics, we knew something was off. revealed the real diagnosis: Normovolemic Normocythemic acute decompensated HF.

❌ Standard diuretics weren't helping

✅ Treating diastolic dysfunction was the answer

💡The lesson? When patients don't respond as expected, question everything.

🎯Accurate phenotyping saves lives.

📖Read more here: https://linkedin.com/pulse/what-would-happen-we-stopped-assuming-all-heart-failure-cnive

06/12/2025

🔬 40% of "anemic" patients actually have dilutional pseudo-anemia, not true anemia. Standard tests can't tell the difference but can. Read more: https://www.linkedin.com/posts/daxorcorporation_heartfailure-bva-activity-7338601695335112704-d4vD?utm_source=share&utm_medium=member_desktop&rcm=ACoAABh7EWABqJPmyYdciYvicG7ZBxRMs4Vo7zQ
Duke Health